ROYALTY PHARMA PLC CLASS A (RPRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RPRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RPRX | EVP and President, Lilly Neuroscience; Independent Director | 53 | ["Executive Vice President and President, Lilly Neuroscience since December 2025","Chief Medical Officer and Head of Development of Denali Therapeutics from June 2015 to November 2025","Various roles at Genentech from 2007 to 2015","Associate Medical Director at Johnson & Johnson from November 2006 to October 2007","Instructor in the Department of Neurology and Neurological Sciences at Stanford University from June 2002 to November 2006","Board certified in neurology and psychiatry between 2004 and 2014","M.D. from Cornell University","B.S. in Biochemical Sciences from Harvard College"] | ["Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
Biography sourced from the proxy statement filing.
Dr. Ho has served as executive vice president and president, Lilly Neuroscience, since December 2025. Previously, Dr. Ho served as the Chief Medical Officer and Head of Development of Denali Therapeutics from June 2015 to November 2025. Dr. Ho joined Denali from Genentech, where she held various roles of increasing responsibility between 2007 and 2015; from October 2014 to June 2015, Dr. Ho served as Vice President, Non-Oncology Early Clinical Development; from November 2013 to October 2014, Dr. Ho served as Senior Group Medical Director, Early Clinical Development; from April 2011 to November 2013, Dr. Ho served as Group Medical Director, Early Clinical Development; from June 2009 to April 2011, Dr. Ho served as Group Medical Director Global Product Development (Inflammation); and from October 2007 to June 2009, Dr. Ho served as Medical Director, Early Clinical Development. From November 2006 to October 2007, Dr. Ho served as Associate Medical Director at Johnson & Johnson, a health care products company. From June 2002 to November 2006, she was an instructor in the Department of Neurology and Neurological Sciences at Stanford University. Dr. Ho completed a residency in neurology at Partners Neurology Residency of the Massachusetts General and Brigham and Women s Hospital and was board certified in neurology and psychiatry between 2004 and 2014. Dr. Ho received her M.D. from Cornell University and her B.S. in Biochemical Sciences from Harvard College. Former Other Public Company Directorships : Beam Therapeutics Inc. (2018-2026) NGM Biopharmaceuticals, Inc. (2020-2025) Qualifications: Dr. Ho was selected to serve on our Board because of her more than 20 years of leadership and therapeutic development experience in the biopharmaceutical industry. She brings both strong business expertise and experience in discovering, developing and commercializing therapies from early-stage planning to late-stage development in neurology, immunology, ophthalmology, infectious disease and rare disease.